Fovinaciclib for First-Line Therapy of Advanced Breast Cancer

Is fovinaciclib plus letrozole or anastrozole effective and safe as first-line treatment in patients with hormone receptor–positive, human epidermal growth factor receptor 2 (; formerly )–negative advanced breast cancer?This phase 3 randomized clinical trial of 417 patients showed that adding fovinaciclib to first-line letrozole or anastrozole conferred significant and clinically meaningful progression-free survival benefit and consistent improvements in other efficacy outcomes, along with manageable safety and unaffected quality of life.These findings support this combination regimen as first-line therapy for patients with hormone receptor–positive, -negative advanced breast cancer.

Corresponding Author: Binghe Xu, MD, PhD, Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, 17 Panjianyuan Nanli, Beijing 100021, China (xubinghe@medmail.com.cn).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.